Is iBio, Inc. (IBIO) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.9% / 30% | 9.5% / 30% | 0.1% / 30% | 109.25% / 5% | ✗ NOT HALAL |
| DJIM | 3.9% / 33% | 9.5% / 33% | 0.1% / 33% | 109.25% / 5% | ✗ NOT HALAL |
| MSCI | 15.1% / 33% | 37.0% / 33% | 0.5% / 33% | 109.25% / 5% | ✗ NOT HALAL |
| S&P | 3.9% / 33% | 9.5% / 33% | 0.1% / 33% | 109.25% / 5% | ✗ NOT HALAL |
| FTSE | 15.1% / 33% | 37.0% / 33% | 0.5% / 50% | 109.25% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -8491.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -70.2% | |
| Return on Assets (ROA) | -37.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$15M |
| Free Cash Flow | -$15M |
| Total Debt | $4M |
| Debt-to-Equity | 4.3 |
| Current Ratio | 9.0 |
| Total Assets | $23M |
Price & Trading
| Last Close | $1.74 |
| 50-Day MA | $2.34 |
| 200-Day MA | $1.43 |
| Avg Volume | 1.7M |
| Beta | 1.2 |
|
52-Week Range
$0.56
| |
About iBio, Inc. (IBIO)
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2–expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is iBio, Inc. (IBIO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), iBio, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is iBio, Inc.'s debt ratio?
iBio, Inc.'s debt ratio is 3.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 15.1%.
What are iBio, Inc.'s key financial metrics?
iBio, Inc. has a market capitalization of $61M, and revenue of $400,000. Return on equity stands at -70.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.